Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) posted its quarterly earnings data on Thursday. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.05, Briefing.com reports. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative return on equity of 79.39%. The business had revenue of $32.49 million during the quarter, compared to the consensus estimate of $30.11 million. During the same period in the previous year, the firm posted ($1.21) earnings per share. The business’s revenue for the quarter was up 37.8% compared to the same quarter last year.
Deciphera Pharmaceuticals Stock Down 1.8 %
DCPH traded down $0.30 on Friday, reaching $16.51. The stock had a trading volume of 1,277,063 shares, compared to its average volume of 716,774. Deciphera Pharmaceuticals has a 12-month low of $6.51 and a 12-month high of $17.20. The business’s 50-day moving average price is $12.77 and its two-hundred day moving average price is $10.49.
Analyst Ratings Changes
Several equities research analysts have recently commented on DCPH shares. SVB Leerink lifted their price objective on shares of Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the stock an “outperform” rating in a research note on Friday. HC Wainwright raised their target price on shares of Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. Finally, JMP Securities raised shares of Deciphera Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a report on Friday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.13.
Institutional Inflows and Outflows
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.